These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
88 related items for PubMed ID: 20647247
1. Persistent microalbuminuria after treatment with renin-angiotensin axis blockers: causes and results of treatment intensification. Robles NR, Velasco J, Espinosa J, Mena C, Angulo E, Micrex Group Investigators. J Renin Angiotensin Aldosterone Syst; 2011 Sep; 12(3):333-9. PubMed ID: 20647247 [Abstract] [Full Text] [Related]
2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR. Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185 [Abstract] [Full Text] [Related]
3. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug. Ohta Y, Tsuchihashi T, Onaka U, Eto K, Ueno M. Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208 [Abstract] [Full Text] [Related]
4. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria. Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, O'Brien RC, Raffaele J, Tsalamandris C, Melbourne Diabetic Nephropathy Study Group. Diabet Med; 2004 Nov; 21(11):1192-9. PubMed ID: 15498085 [Abstract] [Full Text] [Related]
5. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Balamuthusamy S, Srinivasan L, Verma M, Adigopula S, Jalandhara N, Hathiwala S, Smith E. Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325 [Abstract] [Full Text] [Related]
6. Different patterns of one-year evolution of microalbuminuria in hypertensive patients treated with different inhibitors of the renin-angiotensin system. Cotter J, Oliveira P, Cunha P, Polónia J. Rev Port Cardiol; 2008 Nov; 27(11):1395-404. PubMed ID: 19227807 [Abstract] [Full Text] [Related]
7. New treatment guidelines for a patient with diabetes and hypertension. Mogensen CE. J Hypertens Suppl; 2003 Mar; 21(1):S25-30. PubMed ID: 12769164 [Abstract] [Full Text] [Related]
8. [Risk and prevention of diabetic nephropathy]. Ravera M, Re M, Deferrari G. G Ital Nefrol; 2007 Mar; 24 Suppl 38():13-9. PubMed ID: 17922442 [Abstract] [Full Text] [Related]
9. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Robles NR, Romero B, de Vinuesa EG, Sánchez-Casado E, Cubero JJ. Ren Fail; 2010 Jan; 32(2):192-7. PubMed ID: 20199181 [Abstract] [Full Text] [Related]
10. [Hypertension in patients with diabetes]. Poulsen PL, Hansen KW, Gaede PH, Rossing P. Ugeskr Laeger; 2009 Jun 08; 171(24):2031-4. PubMed ID: 19523370 [Abstract] [Full Text] [Related]
11. Manidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockers. Galceran J, Plana J, Felip A, Pou G, Vila J, Sobrino J. Expert Rev Cardiovasc Ther; 2010 Jun 08; 8(6):751-7. PubMed ID: 20528630 [Abstract] [Full Text] [Related]
12. Persistent effects on blood pressure and renal function of perindopril alone or combined with losartan in Lyon hypertensive rats. Naelten G, Liu KL, Chapuis B, Lo M. Am J Hypertens; 2005 May 08; 18(5 Pt 1):699-706. PubMed ID: 15882554 [Abstract] [Full Text] [Related]
13. [The future of renin inhibition]. Uresin AY, Baran E. Turk Kardiyol Dern Ars; 2009 Oct 08; 37 Suppl 7():32-8. PubMed ID: 20019475 [Abstract] [Full Text] [Related]
14. Predictors of long-term beneficial effects on blood pressure after percutaneous transluminal renal angioplasty in atherosclerotic renal artery stenosis. Alhadad A, Mattiasson I, Ivancev K, Lindblad B, Gottsäter A. Int Angiol; 2009 Apr 08; 28(2):106-12. PubMed ID: 19367240 [Abstract] [Full Text] [Related]
15. Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression. Cerezo C, Ruilope LM, Segura J, Garcia-Donaire JA, de la Cruz JJ, Banegas JR, Waeber B, Rabelink TJ, Messerli FH. J Hypertens; 2012 Jan 08; 30(1):204-9. PubMed ID: 22080225 [Abstract] [Full Text] [Related]
16. [Antiproteinuric effect of renin-angiotensin system blockade in patients with normal/lower than 115 mmHg systolic blood pressure]. Gutiérrez E, González E, Morales E, Herrero JC, Manzanera MJ, García JA, Domínguez-Gil B, Hernández E, Praga M. Nefrologia; 2004 Jan 08; 24(6):546-52. PubMed ID: 15683026 [Abstract] [Full Text] [Related]
17. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus. Agha A, Bashir K, Anwar E. Nepal Med Coll J; 2007 Jun 08; 9(2):79-83. PubMed ID: 17899953 [Abstract] [Full Text] [Related]
18. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G, BENEDICT Study Group. J Am Soc Nephrol; 2006 Dec 08; 17(12):3472-81. PubMed ID: 17082240 [Abstract] [Full Text] [Related]
19. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T. Hypertens Res; 2008 Jan 08; 31(1):59-67. PubMed ID: 18360019 [Abstract] [Full Text] [Related]
20. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers? Ruilope LM. Acta Diabetol; 2005 Apr 08; 42 Suppl 1():S33-41. PubMed ID: 15868118 [Abstract] [Full Text] [Related] Page: [Next] [New Search]